MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
Authors:
- George W. SledgeGSGeorge W. Sledge
- Masakazu ToiMTMasakazu Toi
- Patrick NevenPNPatrick Neven
- Joohyuk SohnJSJoohyuk Sohn
- Kenichi InoueKIKenichi Inoue
- Xavier PivotXPXavier Pivot
- Olga BurdaevaOBOlga Burdaeva
- Meena OkeraMOMeena Okera
- Norikazu MasudaNMNorikazu Masuda
- Peter A. KaufmanPKPeter A. Kaufman
- Han KohHKHan Koh
- Eva-Maria GrischkeEGEva-Maria Grischke
Top Cited Papers
- 1 September 2017
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (25) , 2875-2884
Abstract
Purpose: MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC). Patients and Methods: MONARCH 2 was a global, double-blind, phase III study of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 months from the end of adjuvant ET, or while receiving first-line ET for metastatic disease. Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, per label). The primary end point was investigator-assessed progression-free survival (PFS), and key secondary end points included overall survival, objective response rate (ORR), duration of response, clinical benefit rate, quality of life, and safety. Results: Between August 2014 and December 2015, 669 patients were randomly assigned to receive abemaciclib plus fulvestrant (n = 446) or placebo plus fulvestrant (n = 223). Abemaciclib plus fulvestrant significantly extended PFS versus fulvestrant alone (median, 16.4 v 9.3 months; hazard ratio, 0.553; 95% CI, 0.449 to 0.681; P < .001). In patients with measurable disease, abemaciclib plus fulvestrant achieved an ORR of 48.1% (95% CI, 42.6% to 53.6%) compared with 21.3% (95% CI, 15.1% to 27.6%) in the control arm. The most common adverse events in the abemaciclib versus placebo arms were diarrhea (86.4% v 24.7%), neutropenia (46.0% v 4.0%), nausea (45.1% v 22.9%), and fatigue (39.9% v 26.9%). Conclusions: Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.Keywords
This publication has 24 references indexed in Scilit:
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerNew England Journal of Medicine, 2016
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology GuidelineJournal of Clinical Oncology, 2016
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid TumorsCancer Discovery, 2016
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016
- Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directionsWorld Journal of Clinical Oncology, 2014
- Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcomeBreast Cancer Research and Treatment, 2013
- Convergence of Mitogenic Signalling Cascades from Diverse Classes of Receptors at the Cyclin D–Cyclin-Dependent Kinase–pRb-Controlled G1 CheckpointMolecular and Cellular Biology, 1996
- Cyclin D1 protein expression and function in human breast cancerInternational Journal of Cancer, 1994
- Identification of G1 kinase activity for cdk6, a novel cyclin D partner.Molecular and Cellular Biology, 1994
- Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclinsCell, 1992